PPA
PSTX

Parametric Portfolio Associates’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Parametric Portfolio Associates’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$154K Buy
34,470
+21,357
+163% +$96.3K ﹤0.01% 3496
2021
Q4 		$89K Buy
+13,113
New +$89.3K ﹤0.01% 3565
2021
Q3 		– Sell
-36,961
Closed -$370K – 3676
2021
Q2 		$370K Buy
+36,961
New +$331K ﹤0.01% 3199

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Parametric Portfolio Associates's PSTX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Poseida Therapeutics, Inc. Common Stock (PSTX) stake by 163% in Q1 2022, buying an estimated $96.3K and bringing the position to 34,470 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #3496.

Parametric Portfolio Associates first reported a position in PSTX in Q2 2021 and has held it in 3 quarters since. The position peaked at $370K in Q2 2021. 64 funds tracked by Wall St. Rank hold PSTX as of Q1 2022.

  • Parametric Portfolio Associates held 34,470 shares of Poseida Therapeutics, Inc. Common Stock worth $154K as of Q1 2022.
  • Parametric Portfolio Associates bought 21,357 Poseida Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $96.3K.
  • Poseida Therapeutics, Inc. Common Stock made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3496 holding.
  • Parametric Portfolio Associates first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2021 and has held it in 3 quarters since.
  • Parametric Portfolio Associates's Poseida Therapeutics, Inc. Common Stock position peaked at $370K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.